Table 1 Ongoing clinical trials of osimertinib (AZD9291, TAGRISSO)
From: Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Phase | Study population | NCT no. |
|---|---|---|
Phase Ib | EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI | 02143466 |
Phase I | EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI and standard therapy | 02157883 |
Phase I | EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI | 02317016 |
Phase III (ADAURA) | EGFR mutated stage IB–IIIA NSCLC following complete resection with or without adjuvant chemotherapy | 02511106 |
Phase I | EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI | 02197234 |
Phase III | EGFR mutated advanced NSCLC | 02296125 |
Phase III | EGFR T790M mutation-positive NSCLC progressed following therapy with an EGFR TKI | 02474355 |
Phase III | EGFR T790M mutation-positive NSCLC progressed following therapy with an EGFR TKI | 02151981 |
Phase I | EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI | 02503722 |
Phase I | EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI | 02496663 |
Phase I/II | EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI | 01802632 |
Phase I | EGFR mutated advanced NSCLC | 02228369 |
Phase II | EGFR T790M mutation-positive NSCLC progressed following therapy with an EGFR TKI | 02094261 |
Phase II | EGFR T790M mutation-positive NSCLC progressed following therapy with an EGFR TKI | 02442349 |
Phase Ib | EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI | 02520778 |
Phase IIa | Stage IIIB–IV locally advanced or metastatic NSCLC | 02179671 |
Phase I | Chinese patients with EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI | 02529995 |
Phase II | EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI | 02504346 |